#1 Clinical Trials Search in Europe

Rp-1664 Sulfate

This article discusses a Phase 1 clinical trial investigating the use of RP-1664 Sulfate, a novel drug developed by Repare Therapeutics, for patients with advanced solid tumors. The trial aims to assess the safety, effectiveness, and optimal dosing of RP-1664, which is an inhibitor of Polo-Like Kinase 4 (PLK4). This study represents an important step in developing new treatment options for patients with advanced cancers who have limited therapeutic choices.

Table of Contents

What is RP-1664?

RP-1664 SULFATE is a new drug being developed by Repare Therapeutics for the treatment of advanced solid tumors[1]. It is currently in the early stages of clinical testing, specifically in a Phase 1 trial. This means that while the drug shows promise in laboratory studies, it is still being evaluated for safety and effectiveness in humans.

How does RP-1664 work?

RP-1664 is classified as an inhibitor of Polo-Like Kinase 4 (PLK4)[1]. Polo-Like Kinase 4 is an enzyme that plays a crucial role in cell division. By inhibiting this enzyme, RP-1664 may be able to interfere with the rapid cell division that is characteristic of cancer cells, potentially slowing down or stopping tumor growth.

What conditions does RP-1664 treat?

RP-1664 is being studied for the treatment of advanced solid tumors[1]. Solid tumors are abnormal masses of tissue that don’t contain cysts or liquid areas. They may occur in various parts of the body, such as the breast, lung, prostate, or colon. The term “advanced” typically means that the cancer has spread from where it started to other parts of the body or is at a later stage.

Current Research

The ongoing Phase 1 trial for RP-1664 has several objectives[1]:

  • To assess the safety and tolerability of RP-1664 in patients with advanced solid tumors
  • To determine the best dose and schedule for the drug
  • To study how the drug is processed by the body (pharmacokinetics)
  • To evaluate the preliminary anti-tumor activity of RP-1664

The researchers will be looking at various factors, including[1]:

  • The frequency and severity of side effects
  • How the drug is absorbed, distributed, and eliminated from the body
  • Whether tumors shrink or stop growing in response to the treatment
  • How long patients survive without their cancer progressing

Who can participate in the trial?

The trial is open to adult patients (18 years or older) with advanced solid tumors that have not responded to, or have progressed after, standard treatments[1]. Some key eligibility criteria include:

  • Having a life expectancy of at least 4 months
  • Being in relatively good overall health (able to perform daily activities with little assistance)
  • Having measurable disease that can be evaluated for response to treatment
  • Having a tumor with a specific genetic characteristic: gain or amplification of a gene called TRIM37

There are also several factors that would exclude a person from participating, such as certain medical conditions or prior treatments[1].

How is RP-1664 administered?

RP-1664 is given as an oral medication in the form of hard capsules[1]. This means patients can take the drug by mouth, which is often more convenient than medications that need to be injected or given intravenously.

Safety and Side Effects

As this is a Phase 1 trial, one of the main goals is to assess the safety of RP-1664[1]. The researchers will be closely monitoring all participants for any side effects or adverse reactions to the drug. It’s important to note that at this early stage, not all potential side effects may be known.

The trial includes careful monitoring of patients’ organ function, blood counts, and overall health status. Patients will also be regularly assessed for any signs of tumor response or progression[1].

It’s crucial to remember that RP-1664 is still in the early stages of testing. While it shows promise, more research is needed to fully understand its effectiveness and safety profile. Patients considering participation in this or any clinical trial should discuss the potential risks and benefits thoroughly with their healthcare provider.

Aspect Details
Drug Name RP-1664 Sulfate
Drug Type Inhibitor of Polo-Like Kinase 4 (PLK4)
Administration Oral capsules
Target Condition Advanced Solid Tumors
Trial Phase Phase 1
Primary Objectives Assess safety, tolerability, and determine optimal dose
Secondary Objectives Evaluate pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity
Key Eligibility Criteria Adults with advanced solid tumors, TRIM37 gain/amplification, measurable disease
Study Design Dose escalation followed by expansion cohorts

FAQ

  • What is the main purpose of this clinical trial? The main purpose of this clinical trial is to assess the safety and tolerability of RP-1664 in patients with advanced solid tumors, and to determine the optimal dose and schedule for future clinical investigations.
  • Who is eligible to participate in this trial? Eligible participants are adults (18 years or older) with locally advanced or metastatic solid tumors that have progressed or are nonresponsive to available therapies. They must have measurable disease and evidence of TRIM37 gain or amplification in their tumors.
  • What is RP-1664 Sulfate? RP-1664 Sulfate is an investigational drug developed by Repare Therapeutics. It is an inhibitor of Polo-Like Kinase 4 (PLK4) and is being studied as a potential treatment for advanced solid tumors.
  • How is the drug administered in this trial? RP-1664 Sulfate is administered orally in the form of hard capsules. Participants must be able to swallow and retain whole, intact oral medications to be eligible for the trial.
  • What are the main outcomes being measured in this trial? The main outcomes being measured include the incidence and severity of treatment-related side effects, the optimal dose and schedule based on safety and effectiveness data, and preliminary anti-tumor activity such as objective response rate and progression-free survival.

Ongoing Clinical Trials on Rp-1664 Sulfate

  • Study on the Safety and Effects of RP-1664 for Patients with Advanced Solid Tumors

    Not recruiting

    1 1 1
    Investigated drugs:
    Denmark

Glossary

  • Advanced Solid Tumors: Cancers that have spread from where they started to nearby tissues or other parts of the body. These tumors are typically in a later stage and may be more difficult to treat.
  • PLK4 (Polo-Like Kinase 4): An enzyme involved in cell division. RP-1664 is designed to inhibit this enzyme, which may help stop cancer cells from growing and dividing.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.
  • RECIST (Response Evaluation Criteria in Solid Tumors): A standard way to measure how well a cancer patient responds to treatment. It's based on whether tumors shrink, stay the same, or get bigger.
  • INRC (International Neuroblastoma Response Criteria): A set of guidelines used to assess how well patients with neuroblastoma (a type of childhood cancer) respond to treatment.
  • Objective Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • TRIM37: A gene that, when amplified or overexpressed, may contribute to cancer growth. In this trial, patients must have evidence of TRIM37 gain or amplification in their tumors to be eligible.
  • Dose Escalation: A process in clinical trials where the dose of a drug is gradually increased to find the optimal balance between effectiveness and side effects.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-rp-1664-for-patients-with-advanced-solid-tumors/